NPPA caps cancer drug trade margins at 30% of MRP
In short
India’s NPPA has approved a 30% cap on trade margins for non-scheduled cancer drugs. The summary says some markups averaged about 170% and went as high as 700%.
This could lower costs for patients, but the reporting does not say when the cap starts or exactly which medicines are covered.
What the reporting says
India’s NPPA has approved capping trade margins on non-scheduled cancer drugs at 30% of MRP, according to the publisher summary. The reported aim is to curb markups that averaged about 170% and reached 700% in some cases. The source does not say when the cap takes effect, which drugs are covered, or how strictly it will be enforced.
Why it matters
India’s NPPA has approved a 30% cap on trade margins for non-scheduled cancer drugs, targeting reported markups that averaged about 170% and reached 700% in some cases. The move is intended to reduce patient costs and curb pricing gaps in the cancer-drug supply chain. The reporting does not specify implementation timing, the full product scope, or enforcement details.